MacroGenics, Inc. Share Price

Equities

MGNX

US5560991094

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
4.47 USD -4.49% Intraday chart for MacroGenics, Inc. -1.32% -53.53%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 65.17M 5.14B Sales 2025 * 103M 8.09B Capitalization 280M 22.08B
Net income 2024 * -177M -13.96B Net income 2025 * -137M -10.8B EV / Sales 2024 * 3.31 x
Net cash position 2024 * 64M 5.05B Net cash position 2025 * - 0 EV / Sales 2025 * 2.73 x
P/E ratio 2024 *
-1.48 x
P/E ratio 2025 *
-2.25 x
Employees 339
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.49%
1 week-1.32%
Current month+9.29%
1 month+0.45%
3 months-72.17%
6 months-51.99%
Current year-53.53%
More quotes
1 week
4.32
Extreme 4.32
5.19
1 month
4.03
Extreme 4.03
5.20
Current year
3.14
Extreme 3.14
21.88
1 year
3.14
Extreme 3.14
21.88
3 years
2.13
Extreme 2.13
29.16
5 years
2.13
Extreme 2.13
36.48
10 years
2.13
Extreme 2.13
39.90
More quotes
Managers TitleAgeSince
Founder 71 13/08/00
Director of Finance/CFO 57 30/04/08
Chief Tech/Sci/R&D Officer 69 30/06/20
Members of the board TitleAgeSince
Director/Board Member 67 02/01/23
Director/Board Member 74 18/09/13
Director/Board Member 60 30/09/04
More insiders
Date Price Change Volume
14/06/24 4.47 -4.49% 1,011,747
13/06/24 4.68 -6.21% 1,040,368
12/06/24 4.99 +1.22% 1,402,579
11/06/24 4.93 +7.64% 1,518,977
10/06/24 4.58 +1.10% 1,129,746

Delayed Quote Nasdaq, June 14, 2024 at 09:00 pm

More quotes
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
4.47 USD
Average target price
10.8 USD
Spread / Average Target
+141.61%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW